$4.39 Billion in Sales Expected for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) This Quarter

Equities analysts expect Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to post sales of $4.39 billion for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have issued estimates for Regeneron Pharmaceuticals’ earnings, with estimates ranging from $4.21 billion to $4.77 billion. Regeneron Pharmaceuticals reported sales of $2.42 billion in the same quarter last year, which would suggest a positive year over year growth rate of 81.4%. The company is scheduled to report its next earnings report on Friday, February 4th.

According to Zacks, analysts expect that Regeneron Pharmaceuticals will report full year sales of $15.22 billion for the current year, with estimates ranging from $13.44 billion to $15.89 billion. For the next year, analysts expect that the business will post sales of $12.83 billion, with estimates ranging from $11.56 billion to $14.93 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, November 4th. The biopharmaceutical company reported $15.37 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $9.81 by $5.56. The company had revenue of $3.45 billion for the quarter, compared to analysts’ expectations of $2.80 billion. Regeneron Pharmaceuticals had a return on equity of 50.38% and a net margin of 51.65%. Regeneron Pharmaceuticals’s quarterly revenue was up 50.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $7.68 earnings per share.

Several research firms have weighed in on REGN. Morgan Stanley boosted their price objective on Regeneron Pharmaceuticals from $571.00 to $617.00 and gave the stock an “equal weight” rating in a research report on Friday, November 5th. Oppenheimer boosted their price objective on Regeneron Pharmaceuticals from $725.00 to $825.00 and gave the stock an “outperform” rating in a research report on Friday, August 6th. SVB Leerink boosted their price objective on Regeneron Pharmaceuticals from $798.00 to $850.00 and gave the stock an “outperform” rating in a research report on Friday, November 5th. UBS Group began coverage on Regeneron Pharmaceuticals in a research report on Thursday, September 9th. They issued a “buy” rating and a $763.00 price objective on the stock. Finally, Benchmark cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 5th. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Buy” and an average price target of $703.59.

Shares of NASDAQ:REGN traded down $1.14 during mid-day trading on Friday, hitting $648.18. 545,233 shares of the company traded hands, compared to its average volume of 850,101. The stock has a market cap of $69.71 billion, a P/E ratio of 10.35, a P/E/G ratio of 1.16 and a beta of 0.19. The company has a current ratio of 3.71, a quick ratio of 3.16 and a debt-to-equity ratio of 0.11. Regeneron Pharmaceuticals has a 12-month low of $441.00 and a 12-month high of $686.62. The stock has a 50-day moving average price of $606.80 and a two-hundred day moving average price of $588.14.

In related news, CFO Robert E. Landry sold 681 shares of the business’s stock in a transaction dated Wednesday, November 17th. The stock was sold at an average price of $645.08, for a total transaction of $439,299.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director N Anthony Coles sold 11,948 shares of the company’s stock in a transaction dated Wednesday, September 15th. The stock was sold at an average price of $658.98, for a total value of $7,873,493.04. Following the completion of the transaction, the director now owns 7,811 shares of the company’s stock, valued at $5,147,292.78. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 46,079 shares of company stock worth $30,010,914. 11.84% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently bought and sold shares of REGN. Heritage Wealth Advisors purchased a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $30,000. Gleason Group Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $31,000. Arkadios Wealth Advisors boosted its holdings in shares of Regeneron Pharmaceuticals by 96.6% in the 2nd quarter. Arkadios Wealth Advisors now owns 57 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 28 shares in the last quarter. Sandy Spring Bank boosted its holdings in shares of Regeneron Pharmaceuticals by 416.7% in the 2nd quarter. Sandy Spring Bank now owns 62 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 50 shares in the last quarter. Finally, Evoke Wealth LLC boosted its holdings in Regeneron Pharmaceuticals by 427.3% during the 3rd quarter. Evoke Wealth LLC now owns 58 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 47 shares during the period. Hedge funds and other institutional investors own 82.08% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.

Recommended Story: What are no-load funds?

Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.